Astec Lifesciences Peer Comparison

NSE: ASTEC | BSE: 533138

₹710.45

₹-16.05 (-2.21%)

As on 16-Oct-2026IST

Market cap

₹1,584 Cr

Revenue (TTM)

₹441 Cr

P/E Ratio

P/B Ratio

4.3

Div. Yield

0 %

Edit

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Market cap (₹ Cr)	1,584	20,203	16,360	6,541	3,987
Revenue (₹ Cr)	441	3,245	5,595	5,357	2,962
Net Profit (₹ Cr)	-66.56	579.39	732.10	626.21	214.00
Net Margin (%)	-14.93	17.04	12.71	11.46	7.12
RoE (%)	-16.03	17.35	24.05	21.55	13.45
Price to Earnings	--	34.87	22.35	10.45	18.63
Price-To-Book	4.26	5.61	4.98	2.03	1.84

Income Statement (₹ Cr)

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Operating Revenue	440.63	3,244.88	5,595.40	5,356.54	2,962.00
Total Income	445.92	3,400.10	5,760.60	5,464.12	3,005.00
Total Expenditure	434.83	2,559.91	4,702.50	4,309.62	2,566.00
EBITDA	5.79	684.97	892.90	1,046.92	396.00
Depreciation	44.50	67.63	116.90	346.70	118.00
EBIT	-38.70	617.34	776.00	700.22	278.00
Interest	31.22	8.16	19.40	3.01	8.00
Other Income	5.29	155.22	165.20	107.59	43.00
Exceptional Items	-2.09	10.82	0.00	0.00	-24.00
Profit before Tax	-66.72	775.21	921.80	804.80	289.00
Provision for Tax	-0.17	195.82	189.70	178.58	75.00
Profit after Tax	-66.56	579.39	732.10	626.21	214.00

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Shareholder's Funds	390.61	3,389.67	2,965.70	3,136.49	2,043.00
Minority Interest	-0.04	0.06	0.00	-0.09	0.00
Non-Current Liabilities	51.33	110.60	166.20	257.07	78.00
Current Liabilities	499.79	969.81	2,567.50	2,386.20	1,224.00
Total Liabilities	942.08	4,473.76	9,033.00	5,890.22	4,248.66

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Non-Current Assets	448.54	941.45	598.20	1,259.56	844.00
Current Assets	442.99	3,340.15	4,918.30	4,438.10	2,309.00
Total Assets	942.08	4,473.76	9,033.00	5,890.22	4,248.66
Total Debt*	448.93	1.50	0.00	0.00	6.90
Net Current Assets	-56.80	2,370.34	2,350.80	2,051.90	1,085.00
Contingent Liabilities	184.06	60.07	765.30	17.55	274.02

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Cash From Operating Activities	-80.71	445.51	1,078.50	655.69	172.11
Cash Flow from Investing Activities	-4.31	-331.95	72.50	-513.07	-94.88
Cash from Financing Activities	94.49	-82.88	-623.80	-118.28	-66.16
Net Cash Inflow / Outflow	9.47	30.68	527.20	24.34	11.07

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
ROCE (%)	-5.71	23.39	30.08	31.10	13.23
ROE (%)	-16.03	17.35	24.05	21.55	13.45
ROA (%)	-7.30	13.73	13.38	11.92	6.77
EBIT Margin (%)	-8.78	19.02	13.87	13.07	9.39
Net Margin (%)	-14.93	17.04	12.71	11.46	7.12
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Revenue Growth (%)	9.33	-3.61	-2.80	18.52	4.41
EBIT Growth (%)	49.66	-0.95	22.55	68.35	25.23
Net Profit Growth (%)	48.01	3.86	23.56	49.11	24.42
EPS Growth (%)	55.67	2.55	23.56	49.11	60.86
Book Value Growth (%)	66.42	16.84	4.05	25.43	7.28

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Price / Earnings	-24.56	35.36	22.35	10.45	14.48
Price / Book Value	4.26	5.61	4.98	2.03	1.84
Dividend Yield (%)	0.00	0.32	4.12	2.07	1.46
EV/EBITDA	348.73	28.03	16.67	5.69	8.70
Market Cap (₹ Cr)	1,201.88	18,203.86	20,885.70	7,846.59	4,235.19

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Debt to Equity	0.13	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.79	--	--	--	0.00
Current Ratio	0.89	3.44	1.92	1.86	1.89
Quick Ratio	0.61	2.65	1.08	1.39	1.10
Interest Coverage	-1.14	95.97	48.52	268.73	37.13

	Astec Lifesciences	Sumitomo Chemical	Bayer Cropscience	Sharda Cropchem	Rallis India
Debtors to sales (%)	56.22	22.67	19.94	44.60	20.80
Asset Turnover	0.48	0.77	1.02	1.02	0.94
Receivable days	160.92	77.14	56.33	142.20	57.86
Inventory Days	121.29	74.64	122.54	68.45	85.52
Payable days	103.52	95.86	131.57	151.79	126.20
Cash Conversion Cycle	178.69	55.92	47.30	58.86	17.18

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.